(Q43719053)

English

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers (English)

1 reference

Europe PubMed Central

26 November 2017

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

Pier Francesco Ferrucci

4

1 reference

Europe PubMed Central

26 November 2017

author name string

F Bertolini

1

1 reference

Europe PubMed Central

26 November 2017

W Mingrone

2

1 reference

Europe PubMed Central

26 November 2017

A Alietti

3

1 reference

Europe PubMed Central

26 November 2017

E Cocorocchio

5

1 reference

Europe PubMed Central

26 November 2017

F Peccatori

6

1 reference

Europe PubMed Central

26 November 2017

S Cinieri

7

1 reference

Europe PubMed Central

26 November 2017

P Mancuso

8

1 reference

Europe PubMed Central

26 November 2017

C Corsini

9

1 reference

Europe PubMed Central

26 November 2017

A Burlini

10

1 reference

Europe PubMed Central

26 November 2017

E Zucca

11

1 reference

Europe PubMed Central

26 November 2017

G Martinelli

12

1 reference

Europe PubMed Central

26 November 2017

publication date

1 July 2001

1 reference

Europe PubMed Central

26 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

26 November 2017

12

1 reference

Europe PubMed Central

26 November 2017

987-990

1 reference

Europe PubMed Central

26 November 2017

7

1 reference

Europe PubMed Central

26 November 2017

Current role of thalidomide in cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

The thin red line: angiogenesis in normal and malignant hematopoiesis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141009812

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1011141009812

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43719053&oldid=2102812233"